Markman Advisors
Patent Valuation, Monetization and Investments

Blog

Markman Advisors Patent Blog

by Zachary Silbersher

Posts tagged mRNA-1273
Is Moderna’s COVID-19 vaccine using Arbutus Biopharma’s patents?

We previously blogged about Moderna Therapeutics’ ($MRNA) ongoing patent dispute with Arbutus Biopharma ($ABUS). On July 23, 2020, Arbutus prevailed in Moderna’s third IPR challenge to one of its patents, the ‘069 patent. Given that Moderna’s COVID-19 vaccine candidate is currently one of the most promising, the question is, will Moderna’s vaccine infringe Arbutus’ patents?

Read More
Markman AdvisorsModerna Therapeutics, Moderna, $MRNA, MRNA, mRNA-1273, Arbutus Biopharma, Arbutus, $ABUS, ABUS, patent, vaccine, lipid, LNP, 069 patent, IPR, inter partes review, Federal Circuit, COVID-19, coronavirus, Zachary Silbersher, Silbersher, cationic lipid, ionizable lipid Comments
Which patents cover the COVID-19 vaccine candidates for Moderna, AstraZeneca, J&J and Novovax?

A number of companies have announced candidates for a COVID-19 vaccine, including Moderna Therapeutics ($MRNA), AstraZeneca ($AZN), Johnson & Johnson ($JNJ) and Novovax ($NVAX). We looked into the existing landscape of patents that cover many of the existing candidates.

Read More
Markman AdvisorsCOVID-19, COVID, coronavirus, Moderna Therapeutics, Moderna, MRNA, $MRNA, AstraZeneca, $AZN, Johnson & Johnson, Janssen, $JNJ, Novovax, $NVAX, NVAX, patent, vaccine, betacoronavirus, mRNA, AZD1222, ChAdOx1, mRNA-1273, Oxford, adenoviral, AD26.COV2-S, NVX-CoV2373, MERS, Zachary Silbersher, SilbersherComment